Resources

This poster summarizes PATH’s recent activities as part of a consortium lead by the University of Washington to develop the DxBox, a system comprising a portable instrument and low-cost disposable cards. The prototype is being developed to diagnose typhoid fever, dengue fever, rickettsial diseases, malaria, measles, and influenza. PATH’s contributions are immunoassay development, field studies, and user needs assessment. Presented at The American Society of Tropical Medicine and Hygiene (ASTMH), November 12, 2006; Atlanta, GA.

This document provides a summary of the pilot introduction project in Kenya to provide nevirapine syrup to mothers prior to delivery to assist with the prevention of mother-to-child transmission of HIV.

A prototype of a novel diagnostic assay for cervical pre-cancer and cancer has been developed in both a sandwich ELISA-based and a lateral flow–based format (“strip test”). The test specifically detects presence of high-risk HPV-E6 and therefore promises to be of higher predictive value for cervical pre-cancer and cancer than other assays detecting merely presence of HPV. Presented at: 22rd International Papillomavirus Conference and Clinical Workshop, September 1, 2006; Vancouver, Canada.

This poster demonstrates the predictive validity of an assay developed by Arbor Vita and PATH. For this study, cervical swab specimens collected from women screened, diagnosed, and managed in rural settings in China were tested for the presence of HPV-16 DNA then examined for HPV16-E6 expression. Results confirmed E6 is a potential diagnostic marker. Presented at: 23rd Papillomavirus Conference and Clinical Workshop, September 1, 2006; Prague, Czech Republic.

This poster outlines the evaluation of two immunochromatographic strip test platforms for the best limit of detection: one uses an antibody colloidal gold conjugate which is visually interpreted yielding qualitative results, and the other uses an antibody paramagnetic particle conjugate which is read by an instrument yielding quantitative results. The resulting limits of detection of these two methods are compared to the target limit of detection for an E6 assay of ~50 pg. Presented at: 23rd Papillomavirus Conference and Clinical Workshop, September 1, 2006; Prague, Czech Republic.